Several studies have reported that advanced NSCLC patients with the L858R mutation had a shorter overall survival (OS) and/or progression-free survival (PFS) following EGFR TKI therapy compared to those with EGFR exon 19 deletion13, 14, 15. This evidence concerns the gene EGFR and non-small cell lung carcinoma.